

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1-16. (Canceled)

17. (Currently Amended) A method of treating an allergic disorder in a mammal comprising administering to said mammal a therapeutically effective amount of a TCCR agonist antibody or ~~TCCR binding fragment thereof~~ comprising two or more TCCR antigen binding sites, a bispecific TCCR agonist antibody, a heteroconjugate TCCR agonist antibody, or a TCCR agonist diabody.

18-19. (Canceled)

20. (Currently Amended) The method of claim 17, wherein the allergic disorder ~~is selected from the group consisting of~~ asthma, allergic rhinitis, atopic dermatitis, ~~and/or~~ vernal conjunctivitis.

21-22. (Canceled)

23. (Currently Amended) The method of claim 17, wherein the agonist antibody is a monoclonal antibody or fragment thereof comprising two or more TCCR antigen binding sites.

24. (Currently Amended) The method of claim 17, wherein the agonist antibody is a humanized antibody or fragment thereof comprising two or more TCCR antigen binding sites.

25-34. (Canceled)

35. (Previously Presented) The method of claim 17, wherein said agonist is administered in combination with a cytotoxic agent, cytokine, anti-cancer agent, or growth inhibitory agent.

36. (New) The method of claim 17, wherein the bispecific antibody, heteroconjugate antibody, or diabody binds two different TCCR epitopes.
37. (New) The method of claim 17, wherein the antibody fragment is a F(ab')<sub>2</sub> fragment.
38. (New) The method of claim 23, wherein the monoclonal antibody fragment is a F(ab')<sub>2</sub> fragment.
39. (New) The method of claim 24, wherein the humanized antibody fragment is a F(ab')<sub>2</sub> fragment.